Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Sanofi India Limited

NSE: SANOFIPharmaceuticals

Share price

₹2,979.70

-1.46% close of 8 Oct 2026

Market cap ₹6,853 CrP/E 21.1

Business score

How strong the business is, in one number. The parts behind it are in Pro.

68

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹6,853 Cr

P/E ratio

21.1

P/B ratio

8.3

ROCE

57.5%

ROE

41.5%

Dividend yield

2.5%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹4,807.1052-week low ₹2,979.70

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 8.9% over the past year. Meanwhile what it keeps of every 100 rupees of sales improved from 23.8% to 26.5% over the last four years.

Whether it grew faster than its sector

It grew 6.0% a year against a sector median of 13.1% — 7.0 percentage points slower.

Room to re-rate, or risk of de-rating

At 21.1× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 27.9×, the 21st percentile of its own range.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

Profit growthPrice per ₹1 profitPer 1% growth
Sanofi India Limited — this one-13%/yr21.1×—
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 5 of 130 on returns, 97 of 127 on growth, 35 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 57.5% on capital, ahead of 96% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2089 crore of cash from the business, spent ₹43 crore on plant and equipment, and returned ₹4150 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 87 arrived as cash. Its cash comes back more slowly than it used to: it went from being paid 20 days before it paid its own suppliers to waiting 7 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Diabetes grew strongly, but the partnered portfolio still lagged at 2% growth in the quarter.

Announced 4 Aug 2026 · Standalone · Unaudited

Revenue

₹438 Cr

Net profit

₹84 Cr

Net margin

19.1%

EPS

₹36.26

Earnings call transcript · 5 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹6,853 Cr
Prev close
₹2,979.70
52w High
₹4,898
52w Low
₹2,967
Enterprise value
₹6,596 Cr
Beta
0.5
Price CAGR 1y
-36.0%
Price CAGR 3y
-12.0%
Price CAGR 5y
-9.0%
Price CAGR 10y
2.0%

Ratios

Return on assets
23.2%
PEG ratio
-1.5
P/E ratio
21.1
P/B ratio
8.3
EV / EBITDA
13.7
Industry P/E
38.0
ROCE
57.5%
ROCE 5y average
50.8%
ROE
41.5%
Debt / Equity
0.0
Interest coverage
223.5
Dividend yield
2.5%
ROE 3y average
48.0%
ROE last year
43.0%

Annual P&L

Annual revenue
₹1,837 Cr
Annual profit
₹327 Cr
Operating margin
27.0%
Net profit margin
17.8%
EBITDA margin
26.7%
Sales growth 3y
-12.8%
Sales growth 5y
-8.7%
Profit growth 3y
-13.0%
Profit growth 5y
-7.0%
EPS
₹142
Sales growth TTM
-9.0%
Profit growth TTM
-4.0%
Dividend payout
87.0%

Quarter P&L

Sales latest quarter
₹438 Cr
Profit latest quarter
₹84 Cr
YoY quarterly sales growth
7.9%
YoY quarterly profit growth
20.0%
OPM latest quarter
26.0%

Balance Sheet

Book Value
₹359
Face Value
₹10.0
Total debt
₹15 Cr
Total cash
₹369 Cr
Borrowings
₹15 Cr
Reserves / Equity
34.9

Cash Flow

Operating cash flow
₹438 Cr
Free cash flow
₹413 Cr
FCF yield
6.0%
Net cash flow
-₹21 Cr

Shareholding

Promoter holding
60.4%
FII holding
5.7%
DII holding
19.9%
Public holding
14.1%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,749.4033.14,19,7400.902,901.26.015,299.910.520.5
Divi's Lab.9,407.8083.82,49,7480.31902.065.53,080.027.822.0
Torrent Pharma.4,621.7078.81,75,7950.81566.05.84,921.054.915.2
Zydus Lifesci.1,112.2022.81,10,9420.09990.2-35.18,017.022.021.1
Laurus Labs2,019.0099.81,09,0890.10362.1125.52,026.329.117.8
Cipla1,294.9029.21,04,6110.98785.6-39.27,119.32.315.5
Mankind Pharma2,378.0046.098,2220.04574.129.64,030.612.913.5
Sanofi India2,986.2520.06,8772.4983.520.1437.77.757.5
Median414.0034.12,1130.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales515491469511464524515536406475420472438
Expenses393377370374348404397364311341330330322
Material Cost766253555057
Change in Inventories81111-8328369
Purchases of Stock-in-Trade8436270125148159
Employee Cost544542454345
Other Expenses705859775253
Operating Profit1221141001371161201181729513490143115
OPM %24232127252323322328223026
Other Income578277412121439-22346
Exceptional items (within Other Income)00-27000
Interest1000000000100
Depreciation9999991010991099
Profit before tax1691861671691271131221659410283138112
Tax %27181819192725282626262626
Net Profit123152138137103829112070766210384
EPS in Rs53666059453640523033274536
Diluted EPS in Rs523033274536

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Dec 2025
Line itemDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025TTM
Sales1,9772,1932,3672,4602,7713,0712,9022,9572,7702,8512,0131,8371,805
Expenses1,6391,8171,8321,9212,1462,4032,1862,1942,0662,0471,5221,3461,323
Material Cost246
Change in Inventories137
Purchases of Stock-in-Trade514
Employee Cost185
Other Expenses264
Operating Profit339376535538625667716762704804491491483
OPM %17172322232225262528242727
Other Income13121866798833455642048379-8-9
Exceptional items (within Other Income)-27
Interest002110222221.702
Depreciation9711311910210310082674240373736
Profit before tax3734814805156106006771,258864846531445436
Tax %293337373831292528292227
Net Profit264322304326381414478944621603414327324
EPS in Rs115140132142165180208411270262180142141
Diluted EPS in Rs142
Dividend Payout %3946515051194176119211646587

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
-2%
5 years
-9%
3 years
-13%
TTM
-9%

Compounded profit growth

10 years
3%
5 years
-7%
3 years
-13%
TTM
-4%

Stock price CAGR

10 years
2%
5 years
-9%
3 years
-12%
1 year
-36%

Return on equity

10 years
26%
5 years
37%
3 years
48%
Last year
43%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Jun 2026
Equity Capital232323232323232323232323
Reserves1,6041,8602,0032,1962,4192,0962,2031,253992838726803
Borrowings0000023252419191815
Other Liabilities778658751765802777811772681732488567
Total Liabilities2,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,2551,407
Fixed Assets877817769733499464334306315312304291
CWIP223430211710132416181219
Investments000000002000
Other Assets1,5051,6901,9782,2302,7282,4442,7141,7431,3821,2819391,098
Total Assets2,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,2551,407

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operating Activity265213322435374412611559399231462438
Cash from Investing Activity6136-155-79-736627663165136-178-11
Cash from Financing Activity-122-147-180-188-197-183-810-849-1,583-878-392-448
Net Cash Flow205102-1316810429578341-533-612-109-21
Free Cash Flow247184253379317337810574412221426413

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Debtor Days212422292127191817174235
Inventory Days179173169151154127107110125202186127
Days Payable1228179119110100931051098915179
Cash Conversion Cycle781151126165543322331307783
Working Capital Days26979171835-8-20-1924177
ROCE %222627262928323541714958

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters606060606060606060606060
FIIs6.806.316.115.815.785.645.585.615.575.555.655.69
DIIs222323232323232322212120
Public111111111111111112131314
No. of Shareholders68,59862,87061,84967,66266,21166,40168,19666,79071,39575,81375,75880,005

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -36.8% (₹4,713.40 → ₹2,979.70)Brick size ₹60.85 (fixed)Bricks 49
₹3,500₹4,000₹4,500₹2,980Nov '25Feb '26May '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹2,979.70 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-257inr_cr

2025-12-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-06-30

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-06-30

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-06-30

FY revenue / permanent employees + workers, same basis (calc)

1,67,45,670inr

2025-12-31

News

News and filings about Sanofi India Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active pharmaceutical ingredients / pharma raw materials
  • Packaging materials (plastics / multilayer)
  • Purchased stock-in-trade finished pharma products

Buys drug ingredients from

  • Francopia S.A.R.L.
  • Sanofi Healthcare India Private Limited
  • Sanofi-Aventis Singapore Pte. Limited

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE058A01010

Plants

  • Sanofi Goa Manufacturing Site · Goa, Goa

News impact

Big market events that reach Sanofi India Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

22 Apr 2026unspecified₹48
7 Nov 2025interim₹75
25 Apr 2025unspecified₹117
13 Jun 2024demerger₹0
3 May 2024unspecified₹117
7 Mar 2024interim₹50
28 Apr 2023special₹183
28 Apr 2023final₹194

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
24 Sep 2026SANOFI HEALTHCARE INDIA PRIVATE LIMITEDBUY35,00,000₹3,052.00
24 Sep 2026HOECHST GMBHSELL35,00,000₹3,052.00

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
28 Sep 2026Sanofi Healthcare India Private Limited · Promoter GroupBUY35,00,0001,068.20
28 Sep 2026Hoechst GmbH · PromoterSELL35,00,0001,068.20

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.